Therefore, therapeutic reduction of NKG2A expression in NK cells mediated by dasatinib (Chang et al., 2018) could promote HIV control blocking HLA-E:NKG2A interaction and yielding benefit against HIV infection. Here, KLRC1 is linked to HIV infectious disease.